AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion A Randomized Multicenter Study
The purpose of this research study is to determine if the IMPEDE-FX RapidFill System is safe and helps to shrink abdominal aortic aneurysm (AAA) sacs after an endovascular stent graft has been placed.
AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518 IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Despite the advances made with intensive and risk-stratified treatment regimens, 10-20%of children and adolescents with ALL will relapse, and outcomes for those with relapseddisease remain poor despite the use of intensive chemotherapy regimens and HSCT.1-3.Efforts to further escalate the intensity of chemotherapy regimens are limited by toxicity,and targeted agents with novel mechanisms of action are needed to improve outcomes notonly for patients with relapse, but also for newly diagnosed patients with a high risk ofrelapse. This phase 2 single-agent trial will evaluate the adult RP2D of InO (1.8 mg/m2/cycleadministered on a fractionated schedule on day 1, 8, 15 of a 28-day cycle) in pediatricpatients with relapsed or refractory CD22-positive B-ALL. The goal of this study is todocument the toxicity profile of this agent in a pediatric population, as well as determineits efficacy in the relapsed or refractory setting. This safety and efficacy data will lay thefoundation for the incorporation of InO treatment blocks in a randomized fashion intofrontline trials for newly diagnosed high-risk patients
AALL1732 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
The purpose of the study is to determine the safety and efficiency of the investigational medicine Inotuzumab Ozogamicin for patients who have NCI high risk (HR) B-ALL or NCI Standard Risk (SR) B-ALL with certain high risk features. Part 1 of the study is to collect information about your leukemia and chemotherapy is used to try to remove all visible sings of leukemia and allow normal blood cell production to be restored. Depending on your risk group, you may participate in Part II of the study and receive the investigational medicine. There are no experimental medicines that will be given during Part 1 of the study.
AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
This is a Children's Oncology Group (COG) phase 3 trial for children (ages 1-25 years) newly diagnosed with high risk B-lymphoblastic leukemia (HR B-ALL), mixed phenotype acute leukemia (MPAL), or disseminated (Murphy stage III or IV) B-lymphoblastic lymphoma (B-LLy). Patients with HR B-ALL will be stratified into HR favorable B-ALL (HR-Fav) or HR B-ALL. The primary aim of this study is to assess in a randomized fashion whether or not the incorporation of two cycles of inotuzumab ozogamicin (InO) into a modified Berlin-Frankfurt-Munster (mBFM) chemotherapy backbone will improve disease-free survival. InO is an antibody drug conjugate composed of a humanized IgG monoclonal CD22-targeted antibody linked to calicheamicin, a potent antitumor antibiotic. Patients in the other groups will not receive InO but instead will receive mBFM with one interim maintenance (HR-Fav) or two interim maintenance (MPAL and B-LLy) phases. Maintenance duration will be two years following consolidation for all patients regardless of sex.
AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged >/=1 to
The purpose of the study is to study the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.
AAML1831: A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3
This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone.
Abdominal Core Health & Hernia Program | NYU Langone Health
NYU Langone’s Abdominal Core Health and Hernia Program provides simple and complex hernia repair and abdominal wall reconstruction.
Abdominal Core Health & Hernia Program Doctors | NYU Langone Health
Find a doctor at the Abdominal Core Health & Hernia Program at NYU Langone.
Ablation for Kidney Cancer | NYU Langone Health
NYU Langone doctors may use extreme cold or heat, called ablation, to destroy kidney cancer tumors.
Ablation Therapies for Liver Cancer & Liver Metastases | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center may use focused energy or extreme heat therapy, called ablation, to manage liver cancer and liver metastases.